Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.

2.50
Hdl Handle:
http://hdl.handle.net/2336/225275
Title:
Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.
Authors:
Hanly, J G; Urowitz, M B; Su, L; Bae, S-C; Gordon, C; Clarke, A; Bernatsky, S; Vasudevan, A; Isenberg, D; Rahman, A; Wallace, D J; Fortin, P R; Gladman, D; Romero-Diaz, J; Sanchez-Guerrero, J; Dooley, M A; Bruce, I; Steinsson, K; Khamashta, M; Manzi, S; Ramsey-Goldman, R; Sturfelt, G; Nived, O; van Vollenhoven, R; Ramos-Casals, M; Aranow, C; Mackay, M; Kalunian, K; Alarcón, G S; Fessler, B J; Ruiz-Irastorza, G; Petri, M; Lim, S; Kamen, D; Peschken, C; Farewell, V; Thompson, K; Theriault, C; Merrill, J T
Citation:
Ann. Rheum. Dis. 2011, 70(10):1726-32
Issue Date:
Oct-2011
Abstract:
OBJECTIVE: Neuropsychiatric events occur unpredictably in systemic lupus erythematosus (SLE) and most biomarker associations remain to be prospectively validated. This study examined a disease inception cohort of 1047 SLE patients to determine which autoantibodies at enrolment predicted subsequent neuropsychiatric events. METHODS: Patients with a recent SLE diagnosis were assessed prospectively for up to 10 years for neuropsychiatric events using the American College of Rheumatology case definitions. Decision rules of graded stringency determined whether neuropsychiatric events were attributable to SLE. Associations between the first neuropsychiatric event and baseline autoantibodies (lupus anticoagulant (LA), anticardiolipin, anti-β(2) glycoprotein-I, anti-ribosomal P and anti-NR2 glutamate receptor) were tested by Cox proportional hazards regression. RESULTS: Disease duration at enrolment was 5.4 ± 4.2 months, follow-up was 3.6 ± 2.6 years. Patients were 89.1% female with mean (±SD) age 35.2 ± 13.7 years. 495/1047 (47.3%) developed one or more neuropsychiatric event (total 917 events). Neuropsychiatric events attributed to SLE were 15.4% (model A) and 28.2% (model B). At enrolment 21.9% of patients had LA, 13.4% anticardiolipin, 15.1% anti-β(2) glycoprotein-I, 9.2% anti-ribosomal P and 13.7% anti-NR2 antibodies. LA at baseline was associated with subsequent intracranial thrombosis (total n=22) attributed to SLE (model B) (HR 2.54, 95% CI 1.08 to 5.94). Anti-ribosomal P antibody was associated with subsequent psychosis (total n=14) attributed to SLE (model B) (HR 3.92, 95% CI 1.23 to 12.5, p=0.02). Other autoantibodies did not predict neuropsychiatric events. CONCLUSION: In a prospective study of 1047 recently diagnosed SLE patients, LA and anti-ribosomal P antibodies are associated with an increased future risk of intracranial thrombosis and lupus psychosis, respectively.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field.
Additional Links:
http://dx.doi.org/10.1136/ard.2010.148502
Rights:
Archived with thanks to Annals of the rheumatic diseases

Full metadata record

DC FieldValue Language
dc.contributor.authorHanly, J Gen_GB
dc.contributor.authorUrowitz, M Ben_GB
dc.contributor.authorSu, Len_GB
dc.contributor.authorBae, S-Cen_GB
dc.contributor.authorGordon, Cen_GB
dc.contributor.authorClarke, Aen_GB
dc.contributor.authorBernatsky, Sen_GB
dc.contributor.authorVasudevan, Aen_GB
dc.contributor.authorIsenberg, Den_GB
dc.contributor.authorRahman, Aen_GB
dc.contributor.authorWallace, D Jen_GB
dc.contributor.authorFortin, P Ren_GB
dc.contributor.authorGladman, Den_GB
dc.contributor.authorRomero-Diaz, Jen_GB
dc.contributor.authorSanchez-Guerrero, Jen_GB
dc.contributor.authorDooley, M Aen_GB
dc.contributor.authorBruce, Ien_GB
dc.contributor.authorSteinsson, Ken_GB
dc.contributor.authorKhamashta, Men_GB
dc.contributor.authorManzi, Sen_GB
dc.contributor.authorRamsey-Goldman, Ren_GB
dc.contributor.authorSturfelt, Gen_GB
dc.contributor.authorNived, Oen_GB
dc.contributor.authorvan Vollenhoven, Ren_GB
dc.contributor.authorRamos-Casals, Men_GB
dc.contributor.authorAranow, Cen_GB
dc.contributor.authorMackay, Men_GB
dc.contributor.authorKalunian, Ken_GB
dc.contributor.authorAlarcón, G Sen_GB
dc.contributor.authorFessler, B Jen_GB
dc.contributor.authorRuiz-Irastorza, Gen_GB
dc.contributor.authorPetri, Men_GB
dc.contributor.authorLim, Sen_GB
dc.contributor.authorKamen, Den_GB
dc.contributor.authorPeschken, Cen_GB
dc.contributor.authorFarewell, Ven_GB
dc.contributor.authorThompson, Ken_GB
dc.contributor.authorTheriault, Cen_GB
dc.contributor.authorMerrill, J Ten_GB
dc.date.accessioned2012-05-22T13:47:40Z-
dc.date.available2012-05-22T13:47:40Z-
dc.date.issued2011-10-
dc.date.submitted2012-05-22-
dc.identifier.citationAnn. Rheum. Dis. 2011, 70(10):1726-32en_GB
dc.identifier.issn1468-2060-
dc.identifier.pmid21893582-
dc.identifier.doi10.1136/ard.2010.148502-
dc.identifier.urihttp://hdl.handle.net/2336/225275-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field.en_GB
dc.description.abstractOBJECTIVE: Neuropsychiatric events occur unpredictably in systemic lupus erythematosus (SLE) and most biomarker associations remain to be prospectively validated. This study examined a disease inception cohort of 1047 SLE patients to determine which autoantibodies at enrolment predicted subsequent neuropsychiatric events. METHODS: Patients with a recent SLE diagnosis were assessed prospectively for up to 10 years for neuropsychiatric events using the American College of Rheumatology case definitions. Decision rules of graded stringency determined whether neuropsychiatric events were attributable to SLE. Associations between the first neuropsychiatric event and baseline autoantibodies (lupus anticoagulant (LA), anticardiolipin, anti-β(2) glycoprotein-I, anti-ribosomal P and anti-NR2 glutamate receptor) were tested by Cox proportional hazards regression. RESULTS: Disease duration at enrolment was 5.4 ± 4.2 months, follow-up was 3.6 ± 2.6 years. Patients were 89.1% female with mean (±SD) age 35.2 ± 13.7 years. 495/1047 (47.3%) developed one or more neuropsychiatric event (total 917 events). Neuropsychiatric events attributed to SLE were 15.4% (model A) and 28.2% (model B). At enrolment 21.9% of patients had LA, 13.4% anticardiolipin, 15.1% anti-β(2) glycoprotein-I, 9.2% anti-ribosomal P and 13.7% anti-NR2 antibodies. LA at baseline was associated with subsequent intracranial thrombosis (total n=22) attributed to SLE (model B) (HR 2.54, 95% CI 1.08 to 5.94). Anti-ribosomal P antibody was associated with subsequent psychosis (total n=14) attributed to SLE (model B) (HR 3.92, 95% CI 1.23 to 12.5, p=0.02). Other autoantibodies did not predict neuropsychiatric events. CONCLUSION: In a prospective study of 1047 recently diagnosed SLE patients, LA and anti-ribosomal P antibodies are associated with an increased future risk of intracranial thrombosis and lupus psychosis, respectively.en_GB
dc.description.sponsorshipCanadian Institutes of Health Research MOP-57752 MOP-49529 Lupus Foundation of Ontario Ontario Lupus Association Lupus UK Lupus Foundation of America Lupus Alliance of Western New York Conn Smythe Foundation Lupus Flare Foundation Tolfo Family of Toronto, Ontario, Canada MRC (UK) U.1052.00.009 Ministry for Health and Welfare, Republic of Korea A080588 Singer Family Fund for Lupus Research Arthritis Centre of Excellence, University of Toronto NIH UL-1RR-025741 K24-AR-02318 P60-AR-48098 Department of Education, Universities and Research of the Basque Governmenten_GB
dc.language.isoenen
dc.publisherBMJ Publishing Groupen_GB
dc.relation.urlhttp://dx.doi.org/10.1136/ard.2010.148502en_GB
dc.rightsArchived with thanks to Annals of the rheumatic diseasesen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAutoantibodiesen_GB
dc.subject.meshBiological Markersen_GB
dc.subject.meshEpidemiologic Methodsen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshIntracranial Thrombosisen_GB
dc.subject.meshLupus Coagulation Inhibitoren_GB
dc.subject.meshLupus Erythematosus, Systemicen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMental Disordersen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshPrognosisen_GB
dc.subject.meshPsychotic Disordersen_GB
dc.subject.meshRibosomal Proteinsen_GB
dc.subject.meshYoung Adulten_GB
dc.titleAutoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Division of Rheumatology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada. john.hanly@cdha.nshealth.caen_GB
dc.identifier.journalAnnals of the rheumatic diseasesen_GB

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.